• 1
    Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 2005; 128: S748.
  • 2
    Murray JA, Van Dyke C, Plevak MF, et al. Trends in the identification and clinical features of celiac disease in a North American community, 1950–2001. Clin Gastroenterol Hepatol 2003; 1: 1927.
  • 3
    Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002; 346: 1808.
  • 4
    Green PH, Fleischauer AT, Bhagat G, et al. Risk of malignancy in patients with celiac disease. Am J Med 2003; 115: 1915.
  • 5
    Potter DD, Murray JA, Donohue JH, et al. The role of defective mismatch repair in small bowel adenocarcinoma in celiac disease. Cancer Res 2004; 64: 70737.
  • 6
    Leffler DA, Edwards-George J, Dennis M, et al. Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci 2008; 53: 157381.
  • 7
    Gibert A, Espadaler M, Angel Canela M, et al. Consumption of gluten-free products: should the threshold value for trace amounts of gluten be at 20, 100 or 200 p.p.m.? Eur J Gastroenterol Hepatol 2006; 18: 118795.
  • 8
    Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol 2003; 98: 20236.
    Direct Link:
  • 9
    Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85: 1606.
  • 10
    Ciacci C, Cirillo M, Cavallaro R, et al. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 2002; 66: 17885.
  • 11
    Lee SK, Lo W, Memeo L, et al. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003; 57: 18791.
  • 12
    Rubio-Tapia A, Rahim MW, See JA, et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010; 105: 141220.
  • 13
    NIH. National institutes of health consensus development conference statement on celiac disease, June 28–30, 2004. Gastroenterology 2005; 128: S19.
  • 14
    Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 2007; 117: 419.
  • 15
    Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006; 55: 151220.
  • 16
    Smecuol E, Bai JC, Vazquez H, et al. Gastrointestinal permeability in celiac disease. Gastroenterology 1997; 112: 112936.
  • 17
    Schulzke JD, Bentzel CJ, Schulzke I, et al. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 1998; 43: 43541.
  • 18
    Vogelsang H, Schwarzenhofer M, Steiner B, et al. In vivo and in vitro permeability in coeliac disease. Aliment Pharmacol Ther 2001; 15: 141725.
  • 19
    Sander GR, Cummins AG, Henshall T, et al. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett 2005; 579: 48515.
  • 20
    Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003; 171: 616472.
  • 21
    Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006; 169: 19019.
  • 22
    Gopalakrishnan S, Durai M, Kitchens K, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 2012; 35: 8694.
  • 23
    Gopalakrishnan S, Tripathi A, Tamiz AP, et al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 2012; 35: 95101.
  • 24
    Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007; 26: 75766.
  • 25
    Leffler DA, Kelly CP, Zamil HA, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012; 107: 155462.
  • 26
    Johnston SD, Smye M, Watson RP. Intestinal permeability tests in coeliac disease. Clin Lab 2001; 47: 14350.
  • 27
    Svedlund J, Sjodin I, Dotevall G. GSRS–a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 12934.
  • 28
    Dupuy H. The Psychological General Well-Being (PGWB) Index. In: Wenger N, Mattson M, Furberg C, et al., eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing, 1984; 17083.
  • 29
    Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001; 96: 12631.
    Direct Link:
  • 30
    Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroeneterol 2009; 104: 12532.
  • 31
    Linzess (linaclotide) prescribing information. Cambridge, MA: Ironwood Pharmaceuticals, Inc., 2012.
  • 32
    Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; doi: 10.1038/ajg.2012.254 [Epub ahead of print].
  • 33
    Mustalahti K, Lohiniemi S, Collin P, et al. Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 2002; 5: 10513.